Kathy Hibbs, J.D., is an accomplished healthcare technology executive and active board member with more than two decades of expertise in healthcare and genomics. She served as Chief Administrative Officer at
23andMe, Inc. from 2022 to May 2024, and prior to that, as Chief Legal and Regulatory Officer from 2014 to 2022. She is globally recognized for her effectiveness, having successfully pioneered the first FDA clearance for over-the-counter genetic testing.
Regularly recognized as one of the Bay Area’s most influential women by both the San Francisco Business Times and Silicon Valley Business Journal, Kathy is ranked by Chambers as among the most influential general counsel in the US. In addition to our board of directors, Ms. Hibbs sits on the board of directors of Standard BioTools, and previously served on the board of directors of Decipher Biosciences, Inc. and Cadex Genomics, Inc. During her 15 years as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX), Monogram Biosciences, Inc. (NASDAQ: MGRM) and in the leadership team of Varian Medical Systems, Inc. (NASDAQ: VAR) involved in legal, business development and compliance matters, Kathy developed her passion for personalized medicine and the power of innovation to improve the lives of patients. Kathy graduated summa cum laude from the University of California, Riverside, and received her J.D. from UC Law, San Francisco.
What is Kathy L. Hibbs' net worth?
The estimated net worth of Kathy L. Hibbs is at least $718.71 thousand as of September 8th, 2026. Ms. Hibbs owns 96,992 shares of SOPHiA GENETICS stock worth more than $718,711 as of October 11th. This net worth estimate does not reflect any other assets that Ms. Hibbs may own. Learn More about Kathy L. Hibbs' net worth.
How do I contact Kathy L. Hibbs?
Has Kathy L. Hibbs been buying or selling shares of SOPHiA GENETICS?
Kathy L. Hibbs has not been actively trading shares of SOPHiA GENETICS within the last three months. Most recently, Kathy L. Hibbs sold 6,250 shares of the business's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $8.13, for a transaction totalling $50,812.50. Following the completion of the sale, the director now directly owns 96,992 shares of the company's stock, valued at $788,544.96. Learn More on Kathy L. Hibbs' trading history.
Who are SOPHiA GENETICS's active insiders?
SOPHiA GENETICS's insider roster includes Jurgi Camblong (Founder and CEO), George Cardoza (EVP – Chief Financial Officer), Kathy Hibbs (Director), Philippe Menu (Insider), Ross Muken (President), Kevin Puylaert (SVP, Chief Sales Officer), Manuela Valente (Insider), Well Van (Insider), Abhimanyu Verma (EVP, Chief Technology Officer), and Zhenyu Xu (Insider). Learn More on SOPHiA GENETICS's active insiders.
Are insiders buying or selling shares of SOPHiA GENETICS?
In the last twelve months, insiders at the sold shares 109 times. They sold a total of 648,113 shares worth more than $4,009,615.90. The most recent insider tranaction occured on October, 5th when insider
Well Daan Van sold 6,168 shares worth more than $50,084.16. Insiders at SOPHiA GENETICS own 4.9% of the company.
Learn More about insider trades at SOPHiA GENETICS. Information on this page was last updated on 10/5/2026.
